About this deal
Xin, Z. et al. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. Bioorg. Med. Chem. Lett. 18, 4298–4302 (2008).
Finn, R. S. et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38, 193–202 (2020). Raoul, J. L. et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond. Cancer Treat. Rev. 68, 16–24 (2018).Peet, D. J., Janowski, B. A. & Mangelsdorf, D. J. The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8, 571–575 (1998). King, A. J. et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 11100–11105 (2006).
Tian, J., Goldstein, J. L. & Brown, M. S. Insulin induction of SREBP-1c in rodent liver requires LXRalpha-C/EBPbeta complex. Proc. Natl Acad. Sci. USA 113, 8182–8187 (2016). Each of these flavors will be linked to a beloved Marvel Super Hero. Since heroes come in all shapes and sizes, the SUPER LXR™ flavorverse will only continue to expand with innovative offerings and more of your favorite Marvel Super Heroes.
Lee, J. H. et al. Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol. Cell 35, 806–817 (2009).
Related:
